Molecular structure of CPI-0610, CAS Number: 1380087-89-7
CPI-0610 (CAS 1380087-89-7)
Alternate Names:
Pelabresib
CAS Number:
1380087-89-7
Molecular Weight:
365.81
Molecular Formula:
C20H16ClN3O2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
CPI-0610 (CAS 1380087-89-7) References
- BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. | Lui, GYL., et al. 2020. EBioMedicine. 60: 102988. PMID: 32927276
- Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia. | Romine, KA., et al. 2021. Blood Cancer Discov. 2: 518-531. PMID: 34568834
- Histone Modifications and Their Targeting in Lymphoid Malignancies. | Fernández-Serrano, M., et al. 2021. Int J Mol Sci. 23: PMID: 35008680
- Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. | Yamatani, K., et al. 2022. Transl Oncol. 18: 101354. PMID: 35114569
- Ex Vivo Culture Models of Hidradenitis Suppurativa for Defining Molecular Pathogenesis and Treatment Efficacy of Novel Drugs. | Goliwas, KF., et al. 2022. Inflammation. 45: 1388-1401. PMID: 35301634
- JAK Be Nimble: Reviewing the Development of JAK Inhibitors and JAK Inhibitor Combinations for Special Populations of Patients with Myelofibrosis. | Kuykendall, AT. and Komrokji, RS. 2021. J Immunother Precis Oncol. 4: 129-141. PMID: 35663107
- A Novel Acetylation-Immune Subtyping for the Identification of a BET Inhibitor-Sensitive Subgroup in Melanoma. | Wang, L., et al. 2023. Pharmaceuticals (Basel). 16: PMID: 37513949
- Matching-adjusted indirect comparison of the pelabresib-ruxolitinib combination vs JAKi monotherapy in myelofibrosis. | Gupta, V., et al. 2023. Blood Adv. 7: 5421-5432. PMID: 37530627
- A Combination of CPI-0610 and SAHA Induces Apoptosis through STAT3 and p38 Signalling Pathways in Diffuse Large B-cell Lymphoma Cells. | Xu, L., et al. 2023. Curr Med Chem.. PMID: 37916635
- The potential of BRD4 inhibition in tumour mechanosignaling. | Gargalionis, AN., et al. 2023. J Cell Mol Med. 27: 4215-4218. PMID: 37994501
Inhibitor of:
4933408B17Rik, BC032203, BRD1, BRD3, BRD8, BSX, Gm806, MAGE-B4, and WSTF (BAZ1B).Activator of:
1700011H14Rik, Aiolos, BC032203, BRD4, BRDT, BRWD3, IFI-27, and Peregrin.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CPI-0610, 10 mg | sc-507490 | 10 mg | $495.00 |